Neuer Markt Drives German Shopping Spree
Executive Summary
Capitalizing on their hefty valuations, German public biotechs are going on a shopping spree, swapping stock for other companies and thereby creating broader platforms of technologies and in some cases clinical pipelines. In their zest for turning their paper into harder industrial assets, German biotechs are showing themselves far more aggressive than the majority of their American and British counterparts.